Cancer Genetics Announces Conference Call to Discuss First Quarter Results
Cancer Genetics Announces Conference Call to Discuss First Quarter Results
RUTHERFORD, N.J.--(BUSINESS WIRE)-- Cancer Genetics, Inc. (OTCQB: CGIX) ("CGI" or the "Company"), a leader in oncology-focused personalized medicine, will hold a conference call on Thursday, May 16, 2013, at 9:00 a.m. Eastern time to discuss its results for the first quarter ended March 31, 2013.
Cancer Genetics' president and chief executive officer, Panna Sharma, and chief financial officer, Elizabeth Czerepak, will host the call and be available during the question-and-answer session.
To participate in the call, please dial (877) 941-1428, or (480) 629-9665 for international calls, approximately 10 minutes prior to the scheduled start time. Interested parties can also listen via a live Internet webcast, which can be found via the Company's website at http://ir.stockpr.com/cancergenetics/events, or alternately at http://ViaVid.net.
A replay of the call will be available for two weeks from 5:00 p.m. ET on May 16, 2013, until 11:59 p.m. ET on May 30, 2013. The number for the replay is (877) 870-5176, or (858) 384-5517 for international calls; the passcode for the replay is 4619856. In addition, a recording of the call will be available via the Company's website at http://www.cancergenetics.com.
About Cancer Genetics, Inc.
Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services.
CGI's cutting-edge proprietary tests and state-of-the-art reference laboratory provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.
Founded in 1999 by world-renowned cytogeneticist Dr. R.S.K. Chaganti, the Company has been built on a foundation of world-class scientific knowledge and IP in solid and blood-borne cancers, and has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.
Investor Relations
RedChip Companies, Inc.
Jon Cunningham, 800-733-2447, ext. 107
jon@redchip.com
KEYWORDS: United States North America New Jersey
INDUSTRY KEYWORDS:
The article Cancer Genetics Announces Conference Call to Discuss First Quarter Results originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
